Geron Corporation

NASDAQ:GERN

3.49 (USD) • At close December 20, 2024
Bedrijfsnaam Geron Corporation
Symbool GERN
Munteenheid USD
Prijs 3.49
Beurswaarde 2,109,708,490
Dividendpercentage 0%
52-weken bereik 1.64 - 5.34
Industrie Biotechnology
Sector Healthcare
CEO Dr. John A. Scarlett M.D.
Website https://www.geron.com

An error occurred while fetching data.

Over Geron Corporation

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment

Vergelijkbare Aandelen

Stoke Therapeutics, Inc. logo

Stoke Therapeutics, Inc.

STOK

11.68 USD

Tango Therapeutics, Inc. logo

Tango Therapeutics, Inc.

TNGX

3.1 USD

PetIQ, Inc. logo

PetIQ, Inc.

PETQ

30.98 USD

Aura Biosciences, Inc. logo

Aura Biosciences, Inc.

AURA

8.2 USD

GH Research PLC logo

GH Research PLC

GHRS

6.85 USD

Century Therapeutics, Inc. logo

Century Therapeutics, Inc.

IPSC

1.1 USD

Computer Programs and Systems, Inc. logo

Computer Programs and Systems, Inc.

CPSI

9.19 USD

Caribou Biosciences, Inc. logo

Caribou Biosciences, Inc.

CRBU

1.8 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)